UK-US Drug Deal Faced Investigation Request
Six committee chairs have asked the National Audit Office to examine the value of a major trade agreement.
Updated on Sept. 21, 2026 in Healthcare
Live Poll
Do you trust that government pharmaceutical trade deals prioritize the financial interests of the public?
Six parliamentary committee chairs requested a formal investigation by the National Audit Office into the UK-US pharmaceuticals deal announced in December 2025. The request aims to determine if the agreement provides value for money for the public.
Why it matters
The investigation request follows concerns that committees have been unable to obtain necessary impact assessments or information from the government regarding the deal. The probe seeks to evaluate the financial implications of the agreement, which included modified cost-effectiveness thresholds.
The trade deal involves a 25% increase in funding for innovative treatments and a US commitment to zero tariffs on UK pharmaceuticals through January 2029. Reports suggest the agreement carries an estimated extra cost of £3bn to the National Health Service.
The players
National Audit Office
This is the independent parliamentary body that scrutinizes public spending and the value for money of government projects.
National Institute for Health and Care Excellence
This agency provides national guidance and advice to improve health and social care in the UK.
The details
The UK government committed to adjusting the cost-effectiveness thresholds used by the National Institute for Health and Care Excellence (NICE) as part of the trade pact. This policy change coincided with the recent approval of the breast cancer drug Enhertu, which had been previously rejected by NICE in 2024.
Timeline
NICE initially rejected the drug Enhertu in 2024.
The UK-US pharmaceuticals deal was announced in December 2025.
The US tariff-free period began on 1 January 2026.
Committee chairs sent their letter to the NAO on 15 September 2026.
The US tariff-free period is set to end on 19 January 2029.
Market Landscape
This inquiry highlights the tension between international trade obligations and domestic healthcare budgeting priorities. It follows a pattern of heightened scrutiny regarding how trade agreements influence the internal pricing and access policies of the National Health Service.
The investigation could lead to a reassessment of drug pricing and access for patients who rely on treatments approved under the new cost-effectiveness thresholds. Changes in how the NHS budgets for innovative drugs may influence future availability and the cost of care for the public.
The takeaway
The request for an audit signifies a critical moment for transparency in international trade agreements that impact domestic health policy. Citizens should monitor whether future drug approvals under these new cost-effectiveness rules are subject to ongoing financial oversight.
Further reading
Explore more analysis regarding the sector in the Healthcare section.
Source note: This article includes information reported by The Pharmaceutical Journal.
Live Poll
Do you trust that government pharmaceutical trade deals prioritize the financial interests of the public?
